The FDA approved a supplemental Biologics License Application for ixekizumab injection (Taltz, Eli Lilly) for the treatment of active nonradiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation. Ixekizumab is the first interleukin-17A antagonist to be approved by the FDA for nr-axSpA.